GET DAILY SIGNALSWelltower (WELL) vs Healthpeak Properties (DOC): Weighing Two Healthcare REITs
Key Takeaways
- Tickeron AI Verdict: WELL — Welltower currently shows stronger trend consistency, relative momentum, and scale-driven positioning compared with Healthpeak Properties.
- Both names are healthcare real estate investment trusts (REITs), but they serve different segments: DOC spans life-science labs, outpatient medical, and continuing care retirement communities (CCRCs), while WELL concentrates on seniors housing and post-acute/outpatient care.
- Welltower carries a much larger market capitalization and a demographics-driven growth narrative, whereas Healthpeak offers a meaningfully higher dividend yield but faces valuation and execution scrutiny.
- Recent market activity has favored Welltower, which has outperformed the broader market and sector benchmarks, while Healthpeak has traded with less consistent momentum.
- For more detail on each name, explore DOC Major News and DOC Today's Price Move, as well as WELL Major News and WELL Today's Price Move.
- To see which strategies are performing best right now, explore Trending AI Robots.
Introduction
Healthcare REITs continue to attract attention from investors looking for exposure to long-term demographic shifts, such as an aging population and growing demand for medical and senior-living facilities. This comparison focuses on two prominent names in the sector: DOC (Healthpeak Properties) and WELL (Welltower). While both are involved in healthcare real estate, they follow distinct business models, growth drivers, and risk profiles. The analysis matters for income-focused investors balancing dividend yield with capital appreciation, as well as for those assessing relative performance between these large-cap REITs. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Healthpeak Properties (DOC) Overview and Recent Performance
Healthpeak Properties operates as a diversified healthcare REIT with holdings across three main areas: life-science laboratory properties, outpatient medical buildings, and continuing care retirement communities (CCRCs). This setup gives DOC exposure to both biotech research and everyday healthcare delivery. Lately, the stock has been trading in the low-$20 range after recovering from a softer period earlier in the year near the bottom of its 52-week range. Sentiment remains mixed—the company has delivered steady funds from operations (FFO), yet some analysts have lowered price targets, with one firm moving the rating to Hold due to execution and regulatory concerns around its senior-living segment. At a dividend yield near 6%, Healthpeak stands out as an income option, though its growth outlook appears more uncertain than its peer’s.
Welltower (WELL) Overview and Recent Performance
Welltower is a large-cap healthcare REIT primarily focused on seniors housing, post-acute care, and outpatient medical properties in the United States, the United Kingdom, and Canada. With a market capitalization near $180 billion, WELL holds a leading position in the senior-living space and benefits directly from aging demographics alongside limited new supply. The stock has recently traded in the mid-$240s, up roughly 30% year-to-date and ahead of both the broader market and the real estate sector over the past year. Its latest quarterly results showed double-digit normalized FFO growth year-over-year, even as revenue and net income came in slightly below some expectations, leading to a short post-earnings dip. Management also raised forward guidance, reflecting confidence in ongoing demand. From what I see, this momentum stands out when compared to sector peers.
Head-to-Head Comparison
The main difference between the two REITs lies in scale and focus. Welltower centers on seniors housing and related properties, providing a direct connection to demographic trends and a market capitalization about thirteen times larger than Healthpeak’s. Healthpeak spreads its portfolio across life-science labs, outpatient medical, and CCRCs, offering diversification but also greater sensitivity to biotech funding cycles and execution risks in its newer senior-living efforts. On valuation and income, DOC trades at a lower multiple and delivers a higher dividend yield, which appeals to income investors, while WELL carries a premium valuation and lower yield in return for stronger growth and momentum. Risk profiles reflect these differences: Healthpeak contends with sector-specific challenges and more cautious analyst views, whereas Welltower’s primary concerns involve its higher valuation and exposure to interest rates and occupancy levels. Analyst consensus leans toward a Strong Buy for Welltower, compared with a more guarded Hold-leaning stance on Healthpeak. One thing that stands out is how these factors influence relative positioning.
Tickeron AI Verdict
Considering factors such as trend consistency, relative performance, analyst sentiment, and overall scale, Tickeron’s AI would likely favor WELL over DOC in the current setting. Welltower has shown more sustained upward momentum, stronger year-to-date and trailing returns, and a clearer growth driver tied to demographic demand for seniors housing. Healthpeak’s higher yield and diversified holdings are solid attributes, yet its softer momentum and recent analyst caution point to a less steady trend profile. The assessment remains probabilistic rather than absolute—shifts in rates, sector rotation, or a re-rating of Healthpeak’s segments could alter the picture. At present, however, the balance of trend and positioning favors Welltower. I’m watching this closely as market conditions evolve.
Exploring AI-Driven Trading Strategies
When comparing names like DOC and WELL, I often turn to Tickeron’s AI Trading Bots to review automated strategies that have shown strength in similar market environments. These tools help highlight approaches with solid recent results across various timeframes and risk levels, providing an extra layer of data without replacing core fundamental analysis. In my view, this adds useful perspective for investors evaluating relative opportunities in the REIT space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
DOC's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for DOC moved out of overbought territory on November 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In 23 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at 61%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
DOC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on DOC as a result. In 55 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for DOC just turned positive on October 20, 2026. Looking at past instances where DOC's MACD turned positive, the stock continued to rise in 24 of 41 cases over the following month. The odds of a continued upward trend are 59%.
DOC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DOC crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +2.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where DOC advanced for three days, in 148 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 132 of 267 cases where DOC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. DOC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.781) is normal, around the industry mean (3.134). P/E Ratio (57.886) is within average values for comparable stocks, (30.791). DOC's Projected Growth (PEG Ratio) (4.319) is slightly higher than the industry average of (1.649). Dividend Yield (0.020) settles around the average of (0.050) among similar stocks. P/S Ratio (4.787) is also within normal values, averaging (6.013).
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Home Affordable Refinance Program (HARP)?
How Can You Master the Top 15 Rules for Trading Success?
Best Metal Stocks: A Glimpse into the Backbone of Modern Infrastructure
How might the Fidelity Crypto Launch benefit from the current banking turmoil?
FAQ: Are the AI Screener and Time Machine separate subscriptions?
General Information
a real estate investment trust
Industry PublishingBooksMagazines
Advertisement